For the year ending 2025-12-31, PRAX had $141,957K increase in cash & cash equivalents over the period. -$249,124K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Collaboration revenue | 0 |
| Program-specific expenses-Ulixacaltamide | 63,207 |
| Program-specific expenses-Vormatrigine | 74,059 |
| Program-specific expenses-Relutrigine | 45,951 |
| Program-specific expenses-Elsunersen | 6,833 |
| Program-specific expenses-Other Early State Assets | 8,019 |
| Personnel-related expenses | 64,719 |
| Stock-based compensation expense | 33,941 |
| Depreciation expense | 140 |
| Other segment expenses | 29,329 |
| Other income, net | 22,930 |
| Net loss | -303,268 |
| Depreciation expense | 140 |
| Stock-based compensation expense | 33,941 |
| Non-cash operating lease expense | 1,040 |
| Amortization of premiums and discounts on marketable securities, net | 3,592 |
| Non-cash collaboration and license agreement expense | 0 |
| Other non-cash adjustments | 7 |
| Prepaid expenses and other current assets | -640 |
| Accounts payable | 12,097 |
| Accrued expenses | 11,200 |
| Operating lease liabilities | -1,259 |
| Deferred revenue | 0 |
| Other | 0 |
| Net cash used in operating activities | -249,068 |
| Purchases of property and equipment | 56 |
| Purchases of marketable securities | 623,812 |
| Maturities of marketable securities | 312,720 |
| Net cash (used in) provided by investing activities | -311,148 |
| Proceeds from stock offerings, net of issuance costs-Follow On Offering | 567,115 |
| Proceeds from stock offerings, net of issuance costs-License And Collaboration Agreement | 0 |
| Proceeds from stock offerings, net of issuance costs-At The Market Offering | 123,873 |
| Payments of tax withholdings related to vesting of restricted stock units | 2,089 |
| Proceeds from exercise of options and employee stock purchase plan purchases | 13,274 |
| Net cash provided by financing activities | 702,173 |
| Increase in cash, cash equivalents and restricted cash | 141,957 |
Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. (PRAX)